<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394901</url>
  </required_header>
  <id_info>
    <org_study_id>A0081120</org_study_id>
    <nct_id>NCT00394901</nct_id>
  </id_info>
  <brief_title>A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia</brief_title>
  <official_title>A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment
      of postherpetic neuralgia in a dose-ranging manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Scores at Endpoint</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Score at Endpoint by Groups of Subjects With Expected Similar Plasma Concentrations</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 4</measure>
    <time_frame>Week4</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pain Scores at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endpoint Sensory Scores of the Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Sensory score range from 0-33. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Affective Scores of the Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Affective score range from 0-12. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Total Scores of the Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Total score range from 0-45. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Visual Analogue Scale Scores of the Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Visual Analogue Scale Score range from 0-100mm. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Present Pain Intensity Scores of the Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Present pain intensity score range from 0-5. Higher scores indicate more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Endpoint</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Scores range from 0-10. Higher scores indicate more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Disturbance</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for sleep disturbance is 0-100.Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Snoring</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for snoring is 0-100.Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Awaken Short of Breath or With Headache</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for awaken short of breath or with headache is 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Quantity of Sleep</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Sleep Quantity subscale is scored from 0-24 indicating the number of hours of sleep. Higher scores indicate more of the attribute named in the subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Adequacy</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for sleep adequacy is 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Somnolence</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for Somnolence is 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale Scores:Overall Sleep Problem Index</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Score range for overall sleep problem index is 0-100. Higher scores indicate more of the attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Medical Outcomes Study Sleep Scale: Number of Participants With Optimal Sleep</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Number of participants who reported Optimal Sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Patient Global Impression Change</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Patient Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Clinical Global Impression Change</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Clinical Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Physical Functioning</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Physical</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Bodily Pain</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: General Health Perception</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Social Functioning</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Emotional</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Vitality</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint Short-Form 36-Item Health Survey Scores: Mental Health</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Not Reporting Allodynia</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Participants not reporting allodynia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Not Reporting Hyperalgesia</measure>
    <time_frame>Week13/discontinuation</time_frame>
    <description>Participants not reporting hyperalgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 5</measure>
    <time_frame>week 5</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 6</measure>
    <time_frame>week 6</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 7</measure>
    <time_frame>week 7</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 9</measure>
    <time_frame>week 9</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 10</measure>
    <time_frame>week 10</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 11</measure>
    <time_frame>week 11</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 12</measure>
    <time_frame>week 12</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Interference Scores at Week 13</measure>
    <time_frame>week 13</time_frame>
    <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Neuralgia, Postherpetic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 150mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 300mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 600mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).</description>
    <arm_group_label>Pregabalin 150mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).</description>
    <arm_group_label>Pregabalin 300mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).</description>
    <arm_group_label>Pregabalin 600mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visual Analogue Scale (VAS) of pain is higher than 40 mm.

          -  Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

        Exclusion Criteria:

          -  Malignancy within the past 2 years.

          -  Patients who have undergone neurolytic or neurosurgical therapy for postherpetic
             neuralgia.

          -  Creatinine clearance &lt;/= 30 mL/min (estimated from serum creatinine, body weight, age,
             and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).

          -  Patients having other severe pain which may impair the self assessment of the pain due
             to postherpetic neuralgia.

          -  Skin conditions in the affected dermatome that could alter sensation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kasuya-gun</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maebaru</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beppu</city>
        <state>Ohita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitamoto</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081120&amp;StudyName=A%2013-Week%2C%20Randomized%2C%20Double-Blind%2C%20Multicenter%2C%20Placebo-Controlled%20Study%20Of%20Pregabalin%20For%20Postherpetic%20Neuralgia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <results_first_submitted>November 7, 2008</results_first_submitted>
  <results_first_submitted_qc>January 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2009</results_first_posted>
  <last_update_submitted>February 26, 2010</last_update_submitted>
  <last_update_submitted_qc>February 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty (50) centers in Japan</recruitment_details>
      <pre_assignment_details>After a 1-week baseline phase, subjects were stratified into 1 of 2 strata based on their creatinine clearance (CLcr) values (Low, 30 &lt;CLcr &lt;=60 mL/min or Normal, CLcr &gt; 60 mL/min) and then equally randomized into 1 of 4 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin 150 mg/Day</title>
          <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
        </group>
        <group group_id="P3">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98">Subjects randomized</participants>
                <participants group_id="P2" count="87">Subjects randomized</participants>
                <participants group_id="P3" count="90">Subjects randomized</participants>
                <participants group_id="P4" count="97">Subjects randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98">Subjects treated with the study drug.</participants>
                <participants group_id="P2" count="87">Subjects treated with the study drug.</participants>
                <participants group_id="P3" count="89">Subjects treated with the study drug.</participants>
                <participants group_id="P4" count="97">Subjects treated with the study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's Personal Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry into another study was found</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Found not to meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin 150 mg/Day</title>
          <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="97"/>
            <count group_id="B5" value="371"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="8.6"/>
                    <measurement group_id="B2" value="70.2" spread="9.2"/>
                    <measurement group_id="B3" value="70.9" spread="9.8"/>
                    <measurement group_id="B4" value="68.4" spread="12.5"/>
                    <measurement group_id="B5" value="70.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Endpoint</title>
        <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Endpoint</title>
          <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="0.19"/>
                    <measurement group_id="O2" value="4.81" spread="0.20"/>
                    <measurement group_id="O3" value="4.26" spread="0.20"/>
                    <measurement group_id="O4" value="4.49" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.262</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Score at Endpoint by Groups of Subjects With Expected Similar Plasma Concentrations</title>
        <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects who received matching placebo during a 13-week double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Expected Pregabalin Exposure of 300 mg/Day</title>
            <description>Subjects with low CLcr (&gt; 30 and &lt;= 60 mL/min) who received pregabalin 150 mg/day and subjects with normal CLcr (&gt; 60 mL/min) who received pregabalin 300 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Expected Pregabalin Exposure of 600 mg/Day</title>
            <description>Subjects with low CLcr (&gt; 30 and &lt;= 60 mL/min) who received pregabalin 300 mg/day and subjects who received pregabalin 600 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Score at Endpoint by Groups of Subjects With Expected Similar Plasma Concentrations</title>
          <description>Endpoint mean pain score is defined as the mean of the last 7 daily pain diary rating while taking the study medication, up to and including day after last dose. Scores range from 0-10 (11 points ordinal) with higher scores indicating increased pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="0.18"/>
                    <measurement group_id="O2" value="4.35" spread="0.19"/>
                    <measurement group_id="O3" value="4.34" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment group modified based on the expected pregabalin exposure as a factor, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment group modified based on the expected pregabalin exposure as a factor, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders</title>
        <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to endpoint.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to endpoint.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportion of responders were used for the statistical analyses. Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1160</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of responders were used for the statistical analyses. Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Proportion of responders were used for the statistical analyses. Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0107</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 1</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 1</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 1</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" spread="0.17"/>
                    <measurement group_id="O2" value="5.45" spread="0.18"/>
                    <measurement group_id="O3" value="5.21" spread="0.18"/>
                    <measurement group_id="O4" value="5.23" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 2</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 2</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 2</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="0.17"/>
                    <measurement group_id="O2" value="5.27" spread="0.18"/>
                    <measurement group_id="O3" value="4.76" spread="0.18"/>
                    <measurement group_id="O4" value="4.73" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 3</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 3</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 3</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="0.17"/>
                    <measurement group_id="O2" value="5.18" spread="0.18"/>
                    <measurement group_id="O3" value="4.63" spread="0.18"/>
                    <measurement group_id="O4" value="4.60" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Sensory Scores of the Short-Form McGill Pain Questionnaire</title>
        <description>Sensory score range from 0-33. Higher scores indicate more severe pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Sensory Scores of the Short-Form McGill Pain Questionnaire</title>
          <description>Sensory score range from 0-33. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="0.57"/>
                    <measurement group_id="O2" value="8.42" spread="0.61"/>
                    <measurement group_id="O3" value="7.11" spread="0.60"/>
                    <measurement group_id="O4" value="6.97" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.46</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Affective Scores of the Short-Form McGill Pain Questionnaire</title>
        <description>Affective score range from 0-12. Higher scores indicate more severe pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Affective Scores of the Short-Form McGill Pain Questionnaire</title>
          <description>Affective score range from 0-12. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.22"/>
                    <measurement group_id="O2" value="2.14" spread="0.23"/>
                    <measurement group_id="O3" value="1.72" spread="0.23"/>
                    <measurement group_id="O4" value="1.82" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.349</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Total Scores of the Short-Form McGill Pain Questionnaire</title>
        <description>Total score range from 0-45. Higher scores indicate more severe pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Total Scores of the Short-Form McGill Pain Questionnaire</title>
          <description>Total score range from 0-45. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.39" spread="0.75"/>
                    <measurement group_id="O2" value="10.56" spread="0.79"/>
                    <measurement group_id="O3" value="8.84" spread="0.79"/>
                    <measurement group_id="O4" value="8.78" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.441</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.64</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Visual Analogue Scale Scores of the Short-Form McGill Pain Questionnaire</title>
        <description>Visual Analogue Scale Score range from 0-100mm. Higher scores indicate more severe pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Visual Analogue Scale Scores of the Short-Form McGill Pain Questionnaire</title>
          <description>Visual Analogue Scale Score range from 0-100mm. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.02" spread="2.15"/>
                    <measurement group_id="O2" value="47.80" spread="2.28"/>
                    <measurement group_id="O3" value="41.99" spread="2.25"/>
                    <measurement group_id="O4" value="42.59" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.470</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.28</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>-2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>-1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Present Pain Intensity Scores of the Short-Form McGill Pain Questionnaire</title>
        <description>Present pain intensity score range from 0-5. Higher scores indicate more severe pain.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Present Pain Intensity Scores of the Short-Form McGill Pain Questionnaire</title>
          <description>Present pain intensity score range from 0-5. Higher scores indicate more severe pain.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.10"/>
                    <measurement group_id="O2" value="2.01" spread="0.11"/>
                    <measurement group_id="O3" value="1.78" spread="0.11"/>
                    <measurement group_id="O4" value="1.90" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Endpoint</title>
        <description>Scores range from 0-10. Higher scores indicate more severe interference with sleep.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Endpoint</title>
          <description>Scores range from 0-10. Higher scores indicate more severe interference with sleep.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="0.17"/>
                    <measurement group_id="O2" value="2.44" spread="0.18"/>
                    <measurement group_id="O3" value="2.39" spread="0.17"/>
                    <measurement group_id="O4" value="2.26" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Disturbance</title>
        <description>Score range for sleep disturbance is 0-100.Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Disturbance</title>
          <description>Score range for sleep disturbance is 0-100.Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.99" spread="1.88"/>
                    <measurement group_id="O2" value="23.09" spread="2.00"/>
                    <measurement group_id="O3" value="23.75" spread="1.99"/>
                    <measurement group_id="O4" value="20.65" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>-3.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>-2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>-6.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Snoring</title>
        <description>Score range for snoring is 0-100.Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Snoring</title>
          <description>Score range for snoring is 0-100.Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.28" spread="2.57"/>
                    <measurement group_id="O2" value="26.58" spread="2.74"/>
                    <measurement group_id="O3" value="25.24" spread="2.73"/>
                    <measurement group_id="O4" value="31.99" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.95</ci_lower_limit>
            <ci_upper_limit>11.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.417</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.20</ci_lower_limit>
            <ci_upper_limit>10.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.67</ci_lower_limit>
            <ci_upper_limit>16.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Awaken Short of Breath or With Headache</title>
        <description>Score range for awaken short of breath or with headache is 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Awaken Short of Breath or With Headache</title>
          <description>Score range for awaken short of breath or with headache is 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.61"/>
                    <measurement group_id="O2" value="6.70" spread="1.72"/>
                    <measurement group_id="O3" value="6.70" spread="1.69"/>
                    <measurement group_id="O4" value="4.95" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.760</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.83</ci_lower_limit>
            <ci_upper_limit>5.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.754</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>5.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.43</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Quantity of Sleep</title>
        <description>Sleep Quantity subscale is scored from 0-24 indicating the number of hours of sleep. Higher scores indicate more of the attribute named in the subscale.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Quantity of Sleep</title>
          <description>Sleep Quantity subscale is scored from 0-24 indicating the number of hours of sleep. Higher scores indicate more of the attribute named in the subscale.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="0.11"/>
                    <measurement group_id="O2" value="6.59" spread="0.12"/>
                    <measurement group_id="O3" value="6.85" spread="0.12"/>
                    <measurement group_id="O4" value="6.79" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.955</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Adequacy</title>
        <description>Score range for sleep adequacy is 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Sleep Adequacy</title>
          <description>Score range for sleep adequacy is 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.37" spread="2.67"/>
                    <measurement group_id="O2" value="67.38" spread="2.85"/>
                    <measurement group_id="O3" value="73.67" spread="2.82"/>
                    <measurement group_id="O4" value="69.37" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.296</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.52</ci_lower_limit>
            <ci_upper_limit>11.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.87</ci_lower_limit>
            <ci_upper_limit>17.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>13.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Somnolence</title>
        <description>Score range for Somnolence is 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Somnolence</title>
          <description>Score range for Somnolence is 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.23" spread="2.09"/>
                    <measurement group_id="O2" value="34.16" spread="2.23"/>
                    <measurement group_id="O3" value="41.45" spread="2.19"/>
                    <measurement group_id="O4" value="44.46" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>9.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.41</ci_lower_limit>
            <ci_upper_limit>17.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.50</ci_lower_limit>
            <ci_upper_limit>19.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Overall Sleep Problem Index</title>
        <description>Score range for overall sleep problem index is 0-100. Higher scores indicate more of the attribute.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale Scores:Overall Sleep Problem Index</title>
          <description>Score range for overall sleep problem index is 0-100. Higher scores indicate more of the attribute.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.22" spread="1.50"/>
                    <measurement group_id="O2" value="25.19" spread="1.59"/>
                    <measurement group_id="O3" value="26.03" spread="1.58"/>
                    <measurement group_id="O4" value="26.78" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.37</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.52</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Medical Outcomes Study Sleep Scale: Number of Participants With Optimal Sleep</title>
        <description>Number of participants who reported Optimal Sleep</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Medical Outcomes Study Sleep Scale: Number of Participants With Optimal Sleep</title>
          <description>Number of participants who reported Optimal Sleep</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2842</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the optimal sleep score at baseline as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0577</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the optimal sleep score at baseline as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1893</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the optimal sleep score at baseline as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Patient Global Impression Change</title>
        <description>Patient Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Patient Global Impression Change</title>
          <description>Patient Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.2"/>
                    <measurement group_id="O2" value="3.3" spread="1.2"/>
                    <measurement group_id="O3" value="2.9" spread="1.0"/>
                    <measurement group_id="O4" value="3.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0466</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Clinical Global Impression Change</title>
        <description>Clinical Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Clinical Global Impression Change</title>
          <description>Clinical Global Impression Change is scaled from 1 to 7. 1=very much improved, 7=very much worse.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.1"/>
                    <measurement group_id="O2" value="3.1" spread="1.2"/>
                    <measurement group_id="O3" value="2.7" spread="1.1"/>
                    <measurement group_id="O4" value="2.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3440</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by CLcr stratum</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Physical Functioning</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Physical Functioning</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.16" spread="1.28"/>
                    <measurement group_id="O2" value="79.68" spread="1.37"/>
                    <measurement group_id="O3" value="76.93" spread="1.34"/>
                    <measurement group_id="O4" value="77.20" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>7.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Physical</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Physical</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.96" spread="2.26"/>
                    <measurement group_id="O2" value="77.35" spread="2.41"/>
                    <measurement group_id="O3" value="74.63" spread="2.38"/>
                    <measurement group_id="O4" value="69.42" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.01</ci_lower_limit>
            <ci_upper_limit>15.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>12.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.643</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.74</ci_lower_limit>
            <ci_upper_limit>7.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Bodily Pain</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Bodily Pain</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.47" spread="1.82"/>
                    <measurement group_id="O2" value="48.09" spread="1.94"/>
                    <measurement group_id="O3" value="54.54" spread="1.91"/>
                    <measurement group_id="O4" value="52.50" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.811</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.50</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>12.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>10.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: General Health Perception</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: General Health Perception</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.36" spread="1.49"/>
                    <measurement group_id="O2" value="57.66" spread="1.59"/>
                    <measurement group_id="O3" value="56.19" spread="1.57"/>
                    <measurement group_id="O4" value="56.30" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>9.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>7.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>8.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Social Functioning</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Social Functioning</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.28" spread="2.20"/>
                    <measurement group_id="O2" value="77.71" spread="2.35"/>
                    <measurement group_id="O3" value="82.69" spread="2.32"/>
                    <measurement group_id="O4" value="77.11" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>8.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>13.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.18</ci_lower_limit>
            <ci_upper_limit>7.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Emotional</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Role Limitations-Emotional</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.99" spread="2.40"/>
                    <measurement group_id="O2" value="76.14" spread="2.56"/>
                    <measurement group_id="O3" value="75.41" spread="2.52"/>
                    <measurement group_id="O4" value="73.02" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>12.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>12.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.55</ci_lower_limit>
            <ci_upper_limit>9.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Vitality</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Vitality</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.16" spread="1.90"/>
                    <measurement group_id="O2" value="59.80" spread="2.02"/>
                    <measurement group_id="O3" value="61.58" spread="2.00"/>
                    <measurement group_id="O4" value="58.31" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>11.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>12.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>9.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endpoint Short-Form 36-Item Health Survey Scores: Mental Health</title>
        <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoint Short-Form 36-Item Health Survey Scores: Mental Health</title>
          <description>Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.91" spread="1.95"/>
                    <measurement group_id="O2" value="65.90" spread="2.08"/>
                    <measurement group_id="O3" value="68.90" spread="2.05"/>
                    <measurement group_id="O4" value="66.67" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>9.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>12.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>10.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Not Reporting Allodynia</title>
        <description>Participants not reporting allodynia.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Not Reporting Allodynia</title>
          <description>Participants not reporting allodynia.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6451</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0745</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>7.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1787</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Not Reporting Hyperalgesia</title>
        <description>Participants not reporting hyperalgesia.</description>
        <time_frame>Week13/discontinuation</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Not Reporting Hyperalgesia</title>
          <description>Participants not reporting hyperalgesia.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0732</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>5.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0353</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>6.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0393</p_value>
            <method>Regression, Logistic</method>
            <method_desc>treatment, CLcr stratum, and the presence of symptom at baseline as covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>5.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 4</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week4</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 4</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="0.17"/>
                    <measurement group_id="O2" value="5.14" spread="0.18"/>
                    <measurement group_id="O3" value="4.57" spread="0.18"/>
                    <measurement group_id="O4" value="4.50" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 5</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 5</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 5</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.17"/>
                    <measurement group_id="O2" value="5.15" spread="0.18"/>
                    <measurement group_id="O3" value="4.42" spread="0.18"/>
                    <measurement group_id="O4" value="4.55" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.577</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 6</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 6</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.17"/>
                    <measurement group_id="O2" value="5.02" spread="0.18"/>
                    <measurement group_id="O3" value="4.31" spread="0.18"/>
                    <measurement group_id="O4" value="4.54" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 7</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 7</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 7</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="0.17"/>
                    <measurement group_id="O2" value="4.90" spread="0.18"/>
                    <measurement group_id="O3" value="4.24" spread="0.18"/>
                    <measurement group_id="O4" value="4.48" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.334</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 8</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 8</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 8</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="0.17"/>
                    <measurement group_id="O2" value="4.89" spread="0.18"/>
                    <measurement group_id="O3" value="4.23" spread="0.18"/>
                    <measurement group_id="O4" value="4.47" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 9</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 9</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 9</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.17"/>
                    <measurement group_id="O2" value="4.87" spread="0.18"/>
                    <measurement group_id="O3" value="4.22" spread="0.18"/>
                    <measurement group_id="O4" value="4.50" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.392</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 10</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 10</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 10</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.17"/>
                    <measurement group_id="O2" value="4.86" spread="0.18"/>
                    <measurement group_id="O3" value="4.18" spread="0.18"/>
                    <measurement group_id="O4" value="4.56" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.364</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 11</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 11</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 11</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="0.17"/>
                    <measurement group_id="O2" value="4.88" spread="0.18"/>
                    <measurement group_id="O3" value="4.18" spread="0.18"/>
                    <measurement group_id="O4" value="4.47" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 12</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 12</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.17"/>
                    <measurement group_id="O2" value="4.71" spread="0.18"/>
                    <measurement group_id="O3" value="4.15" spread="0.18"/>
                    <measurement group_id="O4" value="4.37" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Scores at Week 13</title>
        <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
        <time_frame>Week 13</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Scores at Week 13</title>
          <description>Weekly mean pain score is defined as the mean of the last 7 daily diary pain ratings. Scores range from 0-10 (11 points ordinal)with higher scores indicating increased pain.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="0.17"/>
                    <measurement group_id="O2" value="4.70" spread="0.18"/>
                    <measurement group_id="O3" value="4.16" spread="0.18"/>
                    <measurement group_id="O4" value="4.36" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis testing was conducted using two-sided tests with significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>repeated measures analysis</method>
            <method_desc>The model included treatment and CLcr stratum as factors, and baseline score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 1</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 1</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 1</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="0.15"/>
                    <measurement group_id="O2" value="3.00" spread="0.16"/>
                    <measurement group_id="O3" value="2.97" spread="0.16"/>
                    <measurement group_id="O4" value="2.81" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 2</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 2</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 2</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.15"/>
                    <measurement group_id="O2" value="2.89" spread="0.16"/>
                    <measurement group_id="O3" value="2.76" spread="0.16"/>
                    <measurement group_id="O4" value="2.49" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 3</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 3</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 3</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.15"/>
                    <measurement group_id="O2" value="2.81" spread="0.16"/>
                    <measurement group_id="O3" value="2.60" spread="0.16"/>
                    <measurement group_id="O4" value="2.43" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 4</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 4</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 4</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.15"/>
                    <measurement group_id="O2" value="2.79" spread="0.16"/>
                    <measurement group_id="O3" value="2.54" spread="0.16"/>
                    <measurement group_id="O4" value="2.36" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 5</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 5</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 5</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="0.15"/>
                    <measurement group_id="O2" value="2.74" spread="0.16"/>
                    <measurement group_id="O3" value="2.39" spread="0.16"/>
                    <measurement group_id="O4" value="2.41" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 6</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 6</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 6</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="0.15"/>
                    <measurement group_id="O2" value="2.63" spread="0.16"/>
                    <measurement group_id="O3" value="2.37" spread="0.16"/>
                    <measurement group_id="O4" value="2.33" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 7</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 7</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 7</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.15"/>
                    <measurement group_id="O2" value="2.55" spread="0.16"/>
                    <measurement group_id="O3" value="2.36" spread="0.16"/>
                    <measurement group_id="O4" value="2.21" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 8</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 8</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 8</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="0.15"/>
                    <measurement group_id="O2" value="2.49" spread="0.16"/>
                    <measurement group_id="O3" value="2.30" spread="0.16"/>
                    <measurement group_id="O4" value="2.14" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 9</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 9</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 9</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="0.15"/>
                    <measurement group_id="O2" value="2.44" spread="0.16"/>
                    <measurement group_id="O3" value="2.38" spread="0.16"/>
                    <measurement group_id="O4" value="2.22" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 10</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 10</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 10</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.15"/>
                    <measurement group_id="O2" value="2.46" spread="0.16"/>
                    <measurement group_id="O3" value="2.39" spread="0.16"/>
                    <measurement group_id="O4" value="2.28" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 11</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 11</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 11</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.15"/>
                    <measurement group_id="O2" value="2.43" spread="0.16"/>
                    <measurement group_id="O3" value="2.37" spread="0.16"/>
                    <measurement group_id="O4" value="2.27" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 12</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 12</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 12</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.15"/>
                    <measurement group_id="O2" value="2.36" spread="0.16"/>
                    <measurement group_id="O3" value="2.28" spread="0.16"/>
                    <measurement group_id="O4" value="2.21" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Interference Scores at Week 13</title>
        <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
        <time_frame>week 13</time_frame>
        <population>Full analysis set. Observed case.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 150 mg/Day</title>
            <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Pregabalin 300 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pregabalin 600 mg/Day</title>
            <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Interference Scores at Week 13</title>
          <description>Weekly mean sleep interference scores is defined as the mean of the last 7 daily diary interference with sleep ratings. Scores range from 0-10 (11 points ordinal) with higher scores indicating more severe interference with sleep.</description>
          <population>Full analysis set. Observed case.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="0.15"/>
                    <measurement group_id="O2" value="2.33" spread="0.16"/>
                    <measurement group_id="O3" value="2.27" spread="0.16"/>
                    <measurement group_id="O4" value="2.19" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>During a 13-week double-blind phase, subjects received matching placebo.</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin 150 mg/Day</title>
          <description>During a 13-week double-blind phase, subjects received pregabalin 150 mg/day.</description>
        </group>
        <group group_id="E3">
          <title>Pregabalin 300 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects received pregabalin 300 mg/day for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Pregabalin 600 mg/Day</title>
          <description>During a 13-week double-blind phase, after 1 week of up titration, subjects with low CLcr received pregabalin 300 mg/day and subjects with normal CLcr received pregabalin 600 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestinal stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

